Schizophrenia: all 3,539 studies

Page 6 of 36. Open to participants first (473), then studies with results posted, then the rest; newest registration first within each.

• Song-making In a Group (SING) R61CompletedNCT05537428Not applicableResults posted
• An Extension Protocol for Patients Who Previously Completed the TMS Pilot StudyTerminatedNCT05526833Not applicableResults posted
• A Study to Evaluate Safety and Tolerability of CVL-231 (Emraclidine) in Adult Participants With SchizophreniaTerminatedNCT05443724Phase 2Results posted
• A Study of Elpipodect (MK-8189) in Participants With Schizophrenia (MK-8189-014)CompletedNCT05406440Phase 1Results posted
• Community Reinforcement and Family Training for Early Psychosis (CRAFT-EP) and Substance Use: A Pilot StudyCompletedNCT05380583Not applicableResults posted
• Study to Assess Adverse Events and Change in Disease Activity of Oral Cariprazine Capsules in Adult Participants With SchizophreniaTerminatedNCT05368558Phase 3Results posted
• Individualized Repetitive Transcranial Magnetic Stimulation for Auditory Verbal HallucinationsTerminatedNCT05319080Not applicableResults posted
• A Trial of 15 and 30 mg Doses of CVL-231 (Emraclidine) in Participants With SchizophreniaCompletedNCT05227703Phase 2Results posted
• A Trial of 10 and 30 mg Doses of CVL-231 (Emraclidine) in Participants With SchizophreniaCompletedNCT05227690Phase 2Results posted
• A Study to Test Long-term Safety of Iclepertin in People With Schizophrenia Who Took Part in a Previous CONNEX StudyTerminatedNCT05211947Phase 3Results posted
• Risk of Mental Health Conditions in Children and Young Adults With Inflammatory Bowel Disease and Influence on HealthCompletedNCT05206734Results posted
• A Study to Assess Efficacy and Safety of Adjunctive KarXT in Subjects With Inadequately Controlled Symptoms of SchizophreniaCompletedNCT05145413Phase 3Results posted
• Evoked Responses as Pharmacodynamic Biomarkers in Healthy and Schizophrenic Participants (MK-4334-007)CompletedNCT05136690Phase 1Results posted
• CBTpro: Scaling up CBT for Psychosis Using Simulated Patients and Spoken Language TechnologiesCompletedNCT05127837Not applicableResults posted
• Brain Stimulation and Cognitive Training - EfficacyCompletedNCT05111548Not applicableResults posted
• Mobile Self-Tracking of Mental HealthCompletedNCT05023252Not applicableResults posted
• Sodium Nitroprusside in Early Course SchizophreniaTerminatedNCT04986072Phase 2Results posted
• Lumateperone for the Prevention of Relapse in Patients With SchizophreniaCompletedNCT04959032Phase 3Results posted
• Feasibility Electrical Stimulation Study for Visual HallucinationsCompletedNCT04870710Not applicableResults posted
• CONNEX-3: A Study to Test Whether Iclepertin Improves Learning and Memory in People With SchizophreniaCompletedNCT04860830Phase 3Results posted
• Memantine Augmentation of Targeted Cognitive Training in SchizophreniaCompletedNCT04857983Phase 2/3Results posted
• Clinical Trial of Iclepertin Effect on Cognition and Functional Capacity in Schizophrenia (CONNEX-2)CompletedNCT04846881Phase 3Results posted
• Clinical Trial of Iclepertin Effect on Cognition and Functional Capacity in Schizophrenia (CONNEX-1)CompletedNCT04846868Phase 3Results posted
• An Open-label Study to Assess the Long-term Safety, Tolerability, and Efficacy of KarXT in Adult Patients With Schizophrenia (EMERGENT-5)CompletedNCT04820309Phase 3Results posted
• Safety, Tolerability, and Pharmacokinetics of Lumateperone in Pediatric Patients With Schizophrenia or Schizoaffective DisorderCompletedNCT04779177Phase 1Results posted
• A Study to Assess Efficacy and Safety of KarXT in Acutely Psychotic Hospitalized Adult Patients With Schizophrenia (EMERGENT-3)CompletedNCT04738123Phase 3Results posted
• Horyzons: Implementation in Clinical PracticeCompletedNCT04673851Not applicableResults posted
• An Extension Study to Assess Long-term Safety, Tolerability, and Efficacy of KarXT in Adult Patients With Schizophrenia (EMERGENT-4)CompletedNCT04659174Phase 3Results posted
• A Study to Assess Efficacy and Safety of KarXT in Acutely Psychotic Hospitalized Adult Patients With Schizophrenia (EMERGENT-2)CompletedNCT04659161Phase 3Results posted
• Efficacy and Safety of Elpipodect (MK-8189) in Participants With an Acute Episode of Schizophrenia (MK-8189-008)CompletedNCT04624243Phase 2Results posted
• A Trial of "Opening Doors to Recovery" for Persons With Serious Mental IllnessesCompletedNCT04612777Not applicableResults posted
• Examining a Digital Health Approach for Advancing Schizophrenia Illness Self-management and Provider EngagementCompletedNCT04602741Not applicableResults posted
• A Multiple Dose Study to Assess the Safety, Tolerability and PK of Risperidone Extended Release CapsulesCompletedNCT04567524Phase 2Results posted
• Pharmacological Modulation of Hippocampal Activity in Psychosis 2CompletedNCT04559529Phase 2Results posted
• Bilateral Repetitive Transcranial Magnetic Stimulation for Auditory Hallucinations ResultsTerminatedNCT04548622Not applicableResults posted
• Efficacy and Safety of Pimavanserin as Adjunctive Treatment for the Negative Symptoms of SchizophreniaCompletedNCT04531982Phase 3Results posted
• In-person vs. Remote Wellness SupportCompletedNCT04526067Not applicableResults posted
• A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Miricorilant in Obese Adult Patients With Schizophrenia While Taking Antipsychotic Medications (GRATITUDE II)CompletedNCT04524403Phase 2Results posted
• A Trial of the Efficacy and the Safety of RO6889450 (Ralmitaront) vs Placebo in Patients With an Acute Exacerbation of Schizophrenia or Schizoaffective DisorderCompletedNCT04512066Phase 2Results posted
• Safety, Tolerability, and Pharmacokinetics Study of Elpipodect (MK-8189) in Participants With Schizophrenia and Healthy Participants (MK-8189-011)CompletedNCT04506905Phase 1Results posted
• Exploring the Effect of Rumination-Focused Cognitive Behaviour Therapy in Patients With SchizophreniaCompletedNCT04442893Not applicableResults posted
• Trial to Investigate the Safety and Efficacy of GWP42003-P Versus Placebo as Adjunctive Therapy in Participants With Schizophrenia Experiencing Inadequate Response to Ongoing Antipsychotic TreatmentTerminatedNCT04421456Phase 2Results posted
• Safety, Tolerability, and Pharmacokinetics of Switching From Oral Risperidone to Risperidone ImplantCompletedNCT04418466Phase 1/2Results posted
• Pharmacologic Augmentation of Targeted Cognitive Training in SchizophreniaCompletedNCT04414930Phase 2Results posted
• Optimizing Cognitive RemediationCompletedNCT04395157Results posted
• Reducing the Burden of Chronic Psychotic Disorders in Tanzania (CAPACITY)CompletedNCT04327843Phase 3Results posted
• Interactions of Fronto-Parietal High Frequency rTMS on Anterior Cingulate Cortex Activation in SchizophreniaCompletedNCT04309370Not applicableResults posted
• A Study of Cognitive Adaptation Training in Inpatient Forensic EnvironmentsCompletedNCT04294719Results posted
• Families With Substance Use and Psychosis: A Pilot StudyCompletedNCT04284813Not applicableResults posted
• Pharmacologic Modulation of Hippocampal Activity in PsychosisTerminatedNCT04277936Phase 2Results posted
• Dexmedetomidine in the Treatment of Agitation Associated With SchizophreniaCompletedNCT04268303Phase 3Results posted
• Models of Auditory HallucinationTerminatedNCT04210557Not applicableResults posted
• Aripiprazole Lauroxil for Preventing Psychotic Relapse After an Initial Schizophrenia EpisodeTerminatedNCT04203056Phase 4Results posted
• rTMS as a Probe of Episodic Memory Neurocircuitry in SchizophreniaCompletedNCT04182113Not applicableResults posted
• Targeting Physical Health in Schizophrenia: Physical Activity Can Enhance Life Randomized Control TrialCompletedNCT04173572Not applicableResults posted
• A Phase 2 Study to Evaluate the Safety and Efficacy of CTP-692 as an Adjunctive Treatment in Adults With SchizophreniaCompletedNCT04158687Phase 2Results posted
• Implementing mHealth for Schizophrenia in Community Mental Health SettingsCompletedNCT04147897Not applicableResults posted
• A Clinical Pharmacology Trial of Brexpiprazole Once-weekly (QW) Formulation Administered as Single and Multiple Oral DosesCompletedNCT04118127Phase 1Results posted
• A Study of the Long-term Safety and Tolerability of an Investigational Drug in People With Schizophrenia.CompletedNCT04115319Phase 3Results posted
• A Clinical Trial That Will Study the Efficacy and Safety of an Investigational Drug in Acutely Psychotic People With SchizophreniaCompletedNCT04092686Phase 3Results posted
• A Study of Paliperidone Palmitate 6-Month FormulationCompletedNCT04072575Phase 3Results posted
• A Clinical Trial to Study the Efficacy and Safety of an Investigational Drug in Acutely Psychotic People With SchizophreniaCompletedNCT04072354Phase 3Results posted
• A Clinical Study to Investigate the Effect of an Investigational Drug as an Added Medication to an Antipsychotic, in Adults With Schizophrenia, as Measured Positron Emission Tomography (PET) ImagingCompletedNCT04038957Phase 1Results posted
• A Trial of Multiple-doses of Aripiprazole in Adults With Schizophrenia or Bipolar 1 DisorderCompletedNCT04030143Phase 1/2Results posted
• Family Psychoeducation for Adults With Psychotic Disorders in TanzaniaCompletedNCT04013932Not applicableResults posted
• The Effects of Kynurenine Aminotransferase Inhibition in People With SchizophreniaCompletedNCT04013555Phase 1/2Results posted
• Novel Pharmacotherapy Approaches in Smokers With Serious Mental IllnessCompletedNCT04011280Phase 4Results posted
• Virtual Reality Training for Social Skills in Schizophrenia - Comparison With Cognitive TrainingCompletedNCT04005794Not applicableResults posted
• Multi-modal Assessment of Gamma-aminobutyric Acid (GABA) Function in PsychosisCompletedNCT04004416Phase 4Results posted
• Cigarette Smoking in Smokers With and Without SchizophreniaCompletedNCT04001114Not applicableResults posted
• Neuroplasticity in TBI and SchizophreniaCompletedNCT03995368Not applicableResults posted
• Rituximab for Schizophrenia Spectrum Disorder (RITS-PS-2019)CompletedNCT03983018Phase 2Results posted
• Safety, Tolerability, Pharmacokinetics and Efficacy of 180 mg Subcutaneous Risperidone From 6 mg Oral RisperidoneCompletedNCT03978832Phase 4Results posted
• Using Digital Media Advertising to Reduce the Duration of Untreated PsychosisCompletedNCT03975400Not applicableResults posted
• Effects of Intranasal Insulin on Neuroimaging Markers and Cognition in Patients With Psychotic DisordersCompletedNCT03943537Phase 2Results posted
• A Pharmaco-imaging Approach to Predicting Social Functioning and Clinical Responses to Oxytocin Administration in SchizophreniaTerminatedNCT03900754Phase 2Results posted
• Efficacy, Safety, and Tolerability of AVP-786 for the Treatment of Negative Symptoms of SchizophreniaTerminatedNCT03896945Phase 2/3Results posted
• Maximizing the Impact of Neuroplasticity Using Transcranial Electrical Stimulation Study 2CompletedNCT03896438Not applicableResults posted
• A Study to Test if TV-46000 is Safe for Maintenance Treatment of SchizophreniaCompletedNCT03893825Phase 3Results posted
• A Trial in Adult Participants With Schizophrenia Treated Prospectively for 6-months With Abilify MyCite®TerminatedNCT03892889Phase 3Results posted
• Improving Visual Attention in SchizophreniaCompletedNCT03880227Not applicableResults posted
• Persistence Targeted Smoking Cessation in Serious Mental Illness (SMI)CompletedNCT03873337Not applicableResults posted
• Study to Evaluate the Efficacy and Safety of Risperidone ISM® in Patients With Acute Schizophrenia: Open Label ExtensionCompletedNCT03870880Phase 3Results posted
• Telmisartan Pilot Study on Treatment Resistant SchizophreniaTerminatedNCT03868839Phase 2Results posted
• Memantine Effects on Sensorimotor Gating and Neurocognition in SchizophreniaCompletedNCT03860597Phase 4Results posted
• This Study Tests Whether BI 425809 Together With Brain Training Using a Computer Improves Mental Functioning in Patients With SchizophreniaCompletedNCT03859973Phase 2Results posted
• Effects of Transdermal Nicotine on Response Inhibition to Emotional Cues in SchizophreniaTerminatedNCT03838484Not applicableResults posted
• Treating Smokers With Mental IllnessCompletedNCT03822416Phase 2Results posted
• Impact of Inflammation on Reward Circuits, Motivational Deficits and Negative Symptoms in SchizophreniaCompletedNCT03818516Not applicableResults posted
• A Study to Assess the Safety, Efficacy, and Pharmacokinetics of Miricorilant (CORT118335) in Obese Adults With Schizophrenia or Bipolar Disorder Treated With Antipsychotic MedicationsCompletedNCT03818256Phase 2Results posted
• ITI-007 (Lumateperone Tosylate) for SchizophreniaTerminatedNCT03817528Phase 2Results posted
• Targeting Physical Health in Schizophrenia: Physical Activity Can Enhance LifeCompletedNCT03757988Not applicableResults posted
• Study of Efficacy of PEAR-004 in SchizophreniaCompletedNCT03751280Phase 2Results posted
• A Study to Evaluate the Safety and Efficacy of BIIB104 in Participants With Cognitive Impairment Associated With Schizophrenia (CIAS)CompletedNCT03745820Phase 2Results posted
• Repetitive TMS & Cognitive Training in Adults With SchizophreniaTerminatedNCT03741751Not applicableResults posted
• D-serine Augmentation of NeuroplasticityCompletedNCT03711500Phase 1/2Results posted
• A Study to Assess Safety and Efficacy of KarXT in Adult Patients With SchizophreniaCompletedNCT03697252Phase 2Results posted
• A Study to Assess the Effects of RO6889450 (Ralmitaront) in Participants With Schizophrenia or Schizoaffective Disorder and Negative SymptomsTerminatedNCT03669640Phase 2Results posted
• CVN058 Effect on Mismatch Negativity in SchizophrenicsCompletedNCT03669250Phase 1Results posted
• Feasibility and Outcomes of a Digital Health Support for the Schizophrenia SpectrumCompletedNCT03649815Early Phase 1Results posted

← Schizophrenia overview